Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798385 | 0.83 | PTGDR2 (0.44) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL30838655 | 0.83 | PTGDR2 (0.44) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL24383529 | 0.83 | P2RX3 (0.46) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL30329765 | 0.82 | P2RX3 (0.45) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL5090357 | 0.82 | P2RX3 (0.45) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL30200681 | 0.82 | P2RX3 (0.45) | PTGDR2P2RX3TLR9TLR7YAP1 | |
| SCHEMBL5096329 | 0.81 | ESR2 (0.44) | P2RX3MGAT2DGAT2 | |
| SCHEMBL5096638 | 0.78 | PPARD (0.48) | PPARGPPARAPPARD | |
| SCHEMBL22366365 | 0.78 | ESR2 (0.46) | P2RX3 | |
| SCHEMBL19679227 | 0.77 | P2RX3 (0.47) | PTGDR2P2RX3TLR9TLR7TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1687299-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREAMTMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051945-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | PPARG, PPARD, PPARA | PPARG 1/4885PTGDR2 234/4885P2RX3 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.